{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:18:23Z","timestamp":1791443903908,"version":"4.3.3"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01074","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T05:05:47Z","timestamp":1594875947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":128,"title":["Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)"],"prefix":"10.3389","volume":"10","author":[{"given":"Andreas","family":"Saltos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiappori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cncr.10841","article-title":"Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America","volume":"95","author":"Janne","year":"2002","journal-title":"Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"259S","DOI":"10.1378\/chest.123.1_suppl.259S","article-title":"Small cell lung cancer","volume":"123","author":"Simon","year":"2003","journal-title":"Chest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.hoc.2003.12.012","article-title":"Treatment of extensive small cell lung cancer","volume":"18","author":"Davies","year":"2004","journal-title":"Hematol Oncol Clin North Am."},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0169-5002(03)00039-4","article-title":"Treatment of relapsed small-cell lung cancer\u2013a focus on the evolving role of topotecan","volume":"40","author":"Rocha Lima","year":"2003","journal-title":"Lung Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1434::AID-CNCR3>3.0.CO;2-C","article-title":"Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study","volume":"77","author":"van Oosterhout","year":"1996","journal-title":"Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","article-title":"Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients","volume":"124","author":"Graus","year":"2001","journal-title":"Brain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddison","year":"1999","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.1997.15.8.2866","article-title":"Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival","volume":"15","author":"Graus","year":"1997","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/tlcr.2018.02.03","article-title":"Targeting DNA damage repair in small cell lung cancer and the biomarker landscape","volume":"7","author":"Sen","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jcb.23400","article-title":"Links between mutant p53 and genomic instability","volume":"113","author":"Hanel","year":"2012","journal-title":"J Cell Biochem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"B17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science."},{"key":"B18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science."},{"key":"B19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ccell.2019.01.011","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"35","author":"Hellmann","year":"2019","journal-title":"Cancer Cell."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/85.4.316","article-title":"Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B","volume":"85","author":"Clamon","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0169-5002(97)00070-6","article-title":"Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B","volume":"19","author":"Clamon","year":"1998","journal-title":"Lung Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/107999002753536130","article-title":"Interferon trials in small cell lung cancer at one institution: a comparison of results obtained before and after initiation of systematic treatment trials using IFN-alpha in combination with other modalities","volume":"22","author":"Ruotsalainen","year":"2002","journal-title":"J Interferon Cytokine Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/0959-8049(92)90526-8","article-title":"Natural interferon alfa as maintenance therapy for small cell lung cancer","author":"Mattson","year":"1992","journal-title":"Eur J Cancer."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1200\/JCO.1994.12.11.2321","article-title":"Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer","volume":"12","author":"Jett","year":"1994","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.1995.13.12.2924","article-title":"Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study","volume":"13","author":"Kelly","year":"1995","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/S0959-8049(97)00174-3","article-title":"Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group","volume":"33","author":"van Zandwijk","year":"1997","journal-title":"Eur J Cancer."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00001813-200002000-00006","article-title":"Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer\u2013a feasibility study","volume":"11","author":"Ruotsalainen","year":"2000","journal-title":"Anticancer Drugs."},{"key":"B31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0169-5002(95)00583-8","article-title":"Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial","volume":"15","author":"Zarogoulidis","year":"1996","journal-title":"Lung Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/107999099314180","article-title":"Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study","volume":"19","author":"Ruotsalainen","year":"1999","journal-title":"J Interferon Cytokine Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00280-014-2427-7","article-title":"Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)","volume":"74","author":"Pillai","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/DDDT.S43184","article-title":"Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study","volume":"7","author":"Zarogoulidis","year":"2013","journal-title":"Drug Des Devel Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nat.2015.0533","article-title":"Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703","volume":"25","author":"Schmidt","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1093\/annonc\/mdy326","article-title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study","volume":"29","author":"Thomas","year":"2018","journal-title":"Ann Oncol."},{"key":"B37","first-page":"679","article-title":"Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant","volume":"2","author":"McCaffery","year":"1996","journal-title":"Clin Cancer Res."},{"key":"B38","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Grant","year":"1999","journal-title":"Clin Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3892\/or.7.4.751","article-title":"Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides","volume":"7","author":"V\u00e1zquez","year":"2000","journal-title":"Oncol Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4161\/cbt.6.2.3574","article-title":"Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial","volume":"6","author":"Neninger","year":"2007","journal-title":"Cancer Biol Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-018-2188-y","article-title":"Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients","volume":"67","author":"Segatori","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-04-0482","article-title":"Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin","volume":"10","author":"Krug","year":"2004","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00262-011-1083-6","article-title":"Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci","volume":"61","author":"Krug","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B45","first-page":"1281","article-title":"Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells","volume":"5","author":"Chikamatsu","year":"1999","journal-title":"Clin Cancer Res."},{"key":"B46","first-page":"2138","article-title":"Gain-of-function mutations in the tumor suppressor gene p53","volume":"6","author":"van Oijen","year":"2000","journal-title":"Clin Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00262-018-2287-9","article-title":"Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer","volume":"68","author":"Chiappori","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","article-title":"Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032","volume":"14","author":"Ready","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"x39","DOI":"10.1093\/annonc\/mdy511.004","article-title":"LBA5 efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331","volume":"29","author":"Reck","year":"2018","journal-title":"Ann Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1200\/JCO.2016.69.0040","article-title":"Theory meets practice for immune checkpoint blockade in small-cell lung cancer","volume":"34","author":"Riess","year":"2016","journal-title":"J Clin Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort","volume":"15","author":"Ready","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"ii77","DOI":"10.1093\/annonc\/mdz094","article-title":"LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase III CheckMate 451 study","volume":"30","author":"Owonikoko","year":"2019","journal-title":"Ann Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2017.35.15_suppl.8503","article-title":"Nivolumab (nivo) \u00b1 ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032","volume":"35","author":"Hellmann","year":"2017","journal-title":"J Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/annonc\/mdw389.03","article-title":"Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)","volume":"27","author":"Sequist","year":"2016","journal-title":"Ann Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"8518","DOI":"10.1200\/JCO.2018.36.15_suppl.8518","article-title":"Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC)","volume":"36","author":"Goldman","year":"2018","journal-title":"J Clin Oncol."},{"key":"B62","volume-title":"FDA Approves Durvalumab for Extensive-State Small Cell Lung Cancer.","year":"2020"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO.2017.35.15_suppl.3058","article-title":"Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) \u00b1 tremelimumab (T): CCTG IND226","volume":"35","author":"Daaboul","year":"2017","journal-title":"J Clin Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"viii596","DOI":"10.1093\/annonc\/mdy298.001","article-title":"Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory\/resistant ED-SCLC from Arm A of the Phase II BALTIC study","volume":"29","author":"Bondarenko","year":"2018","journal-title":"Ann Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1200\/JCO.2018.36.15_suppl.8517","article-title":"Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC)","volume":"36","author":"Cho","year":"2018","journal-title":"J Clin Oncol."},{"key":"B66","volume-title":"Imfinzi Confirmed a Sustainable Overall Survival Benefit in Final Analysis of the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer.","year":"2020"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"CT073","DOI":"10.1158\/1538-7445.AM2019-CT073","article-title":"Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"79","author":"Chung","year":"2019","journal-title":"Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)","volume":"13","author":"Gadgeel","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radonc.2011.08.042","article-title":"Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer","volume":"102","author":"Yee","year":"2012","journal-title":"Radiother Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/S0140-6736(15)60679-1","article-title":"Radiotherapy for extensive stage small-cell lung cancer \u2013 Authors' reply","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet."},{"key":"B74","unstructured":"ClinicalTrials.gov.2020"},{"key":"B75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e000497","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1200\/JCO.2019.37.15_suppl.2553","article-title":"Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies","volume":"37","author":"Uboha","year":"2019","journal-title":"J Clin Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.2174\/1568026619666191009165418","article-title":"Latest advances in small molecule TLR 7\/8 agonist drug research","volume":"19","author":"McGowan","year":"2019","journal-title":"Curr Top Med Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","article-title":"Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial","volume":"20","author":"Tan","year":"2019","journal-title":"Lancet Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/2159-8290.CD-19-0582","article-title":"Combination olaparib and temozolomide in relapsed small cell lung cancer","volume":"10","author":"Farago","year":"2019","journal-title":"Cancer Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e14253","DOI":"10.1200\/JCO.2019.37.15_suppl.e14253","article-title":"Dipeptidyl peptidase inhibitor BXCL701 synergizes with immunomodulatory agents in a preclinical model of colorectal cancer (CRC) by altering the function of various components of the immune system","volume":"37","author":"Agarwal","year":"2019","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"S791","DOI":"10.1016\/j.jtho.2018.08.1379","article-title":"P2.12-03 phase I\/II trial of 177Lu-DOTA0-Tyr3-octreotate (Lutathera) and nivolumab for patients with extensive-stage small cell lung cancer (ES-SCLC)","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/fon-2018-0597","article-title":"ATLANTIS: a phase III study of lurbinectedin\/doxorubicin versus topotecan or cyclophosphamide\/doxorubicin\/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line","volume":"15","author":"Farago","year":"2019","journal-title":"Future Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s10637-016-0410-3","article-title":"Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors","volume":"35","author":"Paz-Ares","year":"2017","journal-title":"Invest New Drugs."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2018.36.15_suppl.8506","article-title":"Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158","volume":"36","author":"Chung","year":"2018","journal-title":"J Clin Onc."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T05:05:52Z","timestamp":1594875952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":91,"alternative-id":["10.3389\/fonc.2020.01074"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01074","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"article-number":"1074"}}